Skip to main content
Top
Published in: Medical Oncology 4/2010

01-12-2010 | Original Paper

mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis

Authors: Quan Zhou, Zhansheng Deng, Yong Zhu, Haitao Long, Shaoxian Zhang, Jiali Zhao

Published in: Medical Oncology | Issue 4/2010

Login to get access

Abstract

The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’ prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
Literature
1.
go back to reference Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–36.PubMedCrossRef Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–36.PubMedCrossRef
2.
go back to reference Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.PubMedCrossRef Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.PubMedCrossRef
3.
go back to reference Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7–18.PubMedCrossRef Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7–18.PubMedCrossRef
4.
go back to reference Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology. 2009;41:149–54.PubMedCrossRef Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology. 2009;41:149–54.PubMedCrossRef
6.
go back to reference Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95–100.PubMedCrossRef Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95–100.PubMedCrossRef
7.
go back to reference Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.PubMedCrossRef Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.PubMedCrossRef
8.
9.
10.
11.
go back to reference Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408–11.PubMed Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408–11.PubMed
12.
go back to reference Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029–40.PubMedCrossRef Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029–40.PubMedCrossRef
13.
go back to reference Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252–9.PubMedCrossRef Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252–9.PubMedCrossRef
14.
go back to reference Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348–59.PubMedCrossRef Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348–59.PubMedCrossRef
15.
go back to reference Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed
16.
go back to reference Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.PubMedCrossRef Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.PubMedCrossRef
17.
go back to reference Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67.PubMedCrossRef Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67.PubMedCrossRef
18.
go back to reference Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531–7.PubMedCrossRef Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531–7.PubMedCrossRef
19.
go back to reference Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864–9.PubMedCrossRef Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864–9.PubMedCrossRef
20.
go back to reference Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393–6.PubMedCrossRef Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393–6.PubMedCrossRef
21.
go back to reference Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679–89.PubMedCrossRef Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679–89.PubMedCrossRef
22.
go back to reference Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.PubMedCrossRef Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.PubMedCrossRef
23.
go back to reference Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.PubMedCrossRef Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.PubMedCrossRef
24.
go back to reference Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.PubMedCrossRef Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.PubMedCrossRef
25.
go back to reference Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.PubMedCrossRef Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.PubMedCrossRef
26.
go back to reference Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.PubMedCrossRef Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.PubMedCrossRef
27.
go back to reference Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.PubMedCrossRef Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.PubMedCrossRef
28.
go back to reference Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.PubMedCrossRef Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.PubMedCrossRef
Metadata
Title
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
Authors
Quan Zhou
Zhansheng Deng
Yong Zhu
Haitao Long
Shaoxian Zhang
Jiali Zhao
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9365-y

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue